Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice Brett H. SimmonsJoseph H. LeeFarbod Shojaei Original Article 09 June 2012 Pages: 213 - 220
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells Tobias BartschtHendrik LehnertHendrik Ungefroren Original Article 15 June 2012 Pages: 221 - 230
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters Geoffrey Y. KuBenjamin A. HaalandGilberto de Lima Lopes Jr. Original Article 15 June 2012 Pages: 231 - 238
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors Iñaki F. TrocónizJosep-María CendrósRosendo Obach Original Article 15 June 2012 Pages: 239 - 250
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors John H. StricklerAlexander N. StarodubHerbert I. Hurwitz Original Article 29 June 2012 Pages: 251 - 258
DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080 Foxiao QiaoDaiying ZuoYingliang Wu Original Article 30 June 2012 Pages: 259 - 270
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902 Young Hak KimMasataka HirabayashiMichiaki Mishima Original Article 30 June 2012 Pages: 271 - 276
Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer Sun Jin SymJunsik HongDong Bok Shin Original Article 30 June 2012 Pages: 277 - 284
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer Sotaro SadahiroToshiyuki SuzukiJunji Uchida Original Article 30 June 2012 Pages: 285 - 291
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer Feby MardjuadiJacques MedioniJean-Pascal Machiels Original Article 01 July 2012 Pages: 293 - 303
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer A. W. TolcherK. N. ChiN. Tran Original Article Open access 03 July 2012 Pages: 305 - 313
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation Su-Hee ChoLee Chun ParkMyung-Ju Ahn Original Article 04 July 2012 Pages: 315 - 320
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase Eric J. SorscherJeong S. HongWilliam B. Parker Original Article 04 July 2012 Pages: 321 - 329
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer Masataka YoshimotoShintaro TakaoJunichi Sakamoto Clinical Trial Report 11 April 2012 Pages: 331 - 338
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1 Abhijit M. GodbolePuranik PurushottamacharVincent C. O. Njar Short Communication 13 May 2012 Pages: 339 - 344
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia Ophelia Q. P. YinFrank J. GilesRichard A. Larson Short Communication 24 May 2012 Pages: 345 - 350
H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia Akihito MatsuokaNaoto TakahashiKenichi Sawada Letter to the Editor 08 June 2012 Pages: 351 - 352